PA8.DE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 lapkr. 2023 @ 18:36):

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide...

Stats
Dzisiejszy wolumen	5 275.00
Średni wolumen	12 639.00
Kapitalizacja rynkowa	2.71M
EPS	€0 ( 2024-04-21 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.129
ATR14	€0.380 (105.56%)

Wolumen Korelacja

Długi: -0.58 (weak negative)

Krótki: 0.13 (neutral)

Signal:(15.842) Neutral

Paion AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Paion AG Korelacja - Waluta/Towar

-0.76
( moderate negative )

-0.81
( strong negative )

0.34
( neutral )

-0.84
( strong negative )

0.53
( weak )

0.47
( neutral )

Paion AG Finanse

Annual	2022
Przychody:	€33.25M
Zysk brutto:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2022
Przychody:	€33.25M
Zysk brutto:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2021
Przychody:	€7.13M
Zysk brutto:	€4.05M (56.83 %)
EPS:	€-0.310

FY	2020
Przychody:	€19.66M
Zysk brutto:	€19.66M (100.00 %)
EPS:	€0.0295

Financial Reports:

No articles found.

Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.